RxDoctor Payments DataLook up a doctor →

Joshua Frame, DO

Internal Medicine · St George, UTNPI 1437143443

Payments from drug & device makers

$214,004in general payments, 2019–2025

Across 1,848 payments — averaging $115.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$204K
  • AbbVie$1K
  • Novartis$973
  • AstraZeneca$911
  • Pfizer$700
  • Novo Nordisk$597
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$10,086100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$214,004 in reported general payments places this provider in the 95th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$467,690
Medicare patients
1,079
Services billed
8,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$135,051
XareltoRivaroxaban111$101,013
OzempicSemaglutide69$100,963
JardianceEmpagliflozin40$69,362
ShingrixVaricella-Zoster Ge/As01b/Pf236$52,215
JanuviaSitagliptin Phosphate31$44,692
MounjaroTirzepatide22$39,394
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$23,805
MyrbetriqMirabegron30$19,482
TradjentaLinagliptin31$19,209
FarxigaDapagliflozin Propanediol18$18,246
VraylarCariprazine Hcl11$15,235
Omeprazole583$9,138
AbrysvoRsv Vacc, Pref A And Pref B/Pf28$8,964
Levothyroxine Sodium705$7,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Premarin$700$149,167174 claims
Johnson & JohnsonXarelto$296$101,013111 claims
Novo NordiskOzempic$597$100,96369 claims
Boehringer IngelheimJardiance, Tradjenta$500$88,57271 claims
GSKShingrix$116$52,215236 claims
MerckJanuvia$181$44,69231 claims
Lilly USA, LLCMounjaro$549$39,39422 claims
AbbVieVraylar, Synthroid$1,473$19,90682 claims
AstraZenecaFarxiga$911$18,24618 claims
Almatica Pharma LLCSertraline Hcl$39$4,335457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 internal medicine providers in Utah.

Other internal medicine in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →